메뉴 건너뛰기




Volumn 18, Issue 1, 2007, Pages 36-47

Ritonavir-Boosted Protease Inhibitors: Impact of Ritonavir on Toxicities in Treatment-Experienced Patients

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR;

EID: 33847316087     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jana.2006.11.003     Document Type: Article
Times cited : (4)

References (47)
  • 2
    • 0037339136 scopus 로고    scopus 로고
    • The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy
    • Becker S.L. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opinion on Investigational Drugs 12 (2003) 401-412
    • (2003) Expert Opinion on Investigational Drugs , vol.12 , pp. 401-412
    • Becker, S.L.1
  • 3
    • 33847335433 scopus 로고    scopus 로고
    • Boehringer Ingelheim Pharmaceuticals, Inc. (2005). Tipranavir [package insert]. Ridgefield, CT: Author.
  • 4
    • 1542613860 scopus 로고    scopus 로고
    • Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: Immunovirological outcome and side effects
    • Bongiovanni M., Bini T., Chiesa E., Cicconi P., Adorni F., and Monforte d'Arminio A. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: Immunovirological outcome and side effects. Antiviral Research 62 (2004) 53-56
    • (2004) Antiviral Research , vol.62 , pp. 53-56
    • Bongiovanni, M.1    Bini, T.2    Chiesa, E.3    Cicconi, P.4    Adorni, F.5    Monforte d'Arminio, A.6
  • 5
    • 33645498764 scopus 로고    scopus 로고
    • Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)
    • Boyd M.A., Srasuebkul P., Khongphattanayothin M., Ruxrungtham K., Hassink E.A.M., Duncombe C.J., et al. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 2006 11 (2006) 223-232
    • (2006) Antiviral Therapy, 2006 , vol.11 , pp. 223-232
    • Boyd, M.A.1    Srasuebkul, P.2    Khongphattanayothin, M.3    Ruxrungtham, K.4    Hassink, E.A.M.5    Duncombe, C.J.6
  • 6
    • 33847304903 scopus 로고    scopus 로고
    • Bristol-Myers Squibb. (2005). Atazanavir [package insert]. Princeton, NJ: Author.
  • 7
    • 33847289174 scopus 로고    scopus 로고
    • Brown T. T., Cole S. R., Li X., Kingsley L. A., Palella F. J., Jr., Riddler S. A., et al. (2004, February). Prevalence and incidence of pre-diabetes and diabetes in the Multicenter AIDS Cohort Study. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
  • 8
    • 19344373051 scopus 로고    scopus 로고
    • Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study
    • Brown T.T., Cole S.R., Li X., Kingsley L.A., Palella F.J., Riddler S.A., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Archives of Internal Medicine 165 (2005) 1179-1184
    • (2005) Archives of Internal Medicine , vol.165 , pp. 1179-1184
    • Brown, T.T.1    Cole, S.R.2    Li, X.3    Kingsley, L.A.4    Palella, F.J.5    Riddler, S.A.6
  • 9
    • 0032971472 scopus 로고    scopus 로고
    • Ritonavir and saquinavir combination therapy for the treatment of HIV infection
    • Cameron D.W., Japour A.J., Xu Y., Hsu A., Mellors J., Farthing C., et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13 (1999) 213-224
    • (1999) AIDS , vol.13 , pp. 213-224
    • Cameron, D.W.1    Japour, A.J.2    Xu, Y.3    Hsu, A.4    Mellors, J.5    Farthing, C.6
  • 10
    • 0033200240 scopus 로고    scopus 로고
    • The rabbit study: Ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients
    • Churchill D.R., Pym A.S., Galpin S., Foxall R., Stainsby C., Clarke J.R., et al. The rabbit study: Ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. AIDS Research and Human Retroviruses 15 (1999) 1181-1189
    • (1999) AIDS Research and Human Retroviruses , vol.15 , pp. 1181-1189
    • Churchill, D.R.1    Pym, A.S.2    Galpin, S.3    Foxall, R.4    Stainsby, C.5    Clarke, J.R.6
  • 11
    • 33847251486 scopus 로고    scopus 로고
    • Clumeck N., Brun S., Sylte J., Isaacson J., Chen S., Lazzarin A., et al. (2001, February). Kaletra (ABT-378/r) and efavirenz: One-year safety/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patients. Paper presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. Abstract No. 525.
  • 13
    • 0002764694 scopus 로고    scopus 로고
    • Drug biotransformation
    • Katzung B.G. (Ed), Lange Medical Books/McGraw-Hill, Medical Publishing Division, New York
    • Correia M.A. Drug biotransformation. In: Katzung B.G. (Ed). Basic & clinical pharmacology. 9th ed. (2004), Lange Medical Books/McGraw-Hill, Medical Publishing Division, New York
    • (2004) Basic & clinical pharmacology. 9th ed.
    • Correia, M.A.1
  • 14
    • 0037251643 scopus 로고    scopus 로고
    • Lopinavir/ritonavir: A review of its use in the management of HIV infection
    • Cvetkovic R.S., and Goa K.L. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 63 (2003) 769-802
    • (2003) Drugs , vol.63 , pp. 769-802
    • Cvetkovic, R.S.1    Goa, K.L.2
  • 15
    • 33847282803 scopus 로고    scopus 로고
    • DeJesus E., Grinsztejn B., Rodriguez C., Nieto-Cisneros L., Coco J., Lazzarin A., et al. (2004, February). Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) vs. lopinavir/ritonavir (LPV/RTV) in patients who have experienced virologic failure on multiple HAART regimens: 48-week results from BMS AI424-045. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. Abstract No. 547.
  • 16
    • 33847299890 scopus 로고    scopus 로고
    • DeJesus E., LaMarca A., Sension M., Beltran C., Yeni P. (2003, February). The CONTEXT study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
  • 17
    • 0141612910 scopus 로고    scopus 로고
    • Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 Trial
    • Dragsted U.B., Gerstoft J., Pedersen C., Peters B., Duran A., Obel N., et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 Trial. Journal of Infectious Diseases 188 (2003) 635-642
    • (2003) Journal of Infectious Diseases , vol.188 , pp. 635-642
    • Dragsted, U.B.1    Gerstoft, J.2    Pedersen, C.3    Peters, B.4    Duran, A.5    Obel, N.6
  • 18
    • 33847299395 scopus 로고    scopus 로고
    • Elston, R. C., Yates, P., Tisdale, M., Richards, N., White, S., DeJesus, E. (2004, July). GW433908 (908)/ritonavir (r): 48 week results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype. Paper presented at the XV International AIDS Conference, Bangkok, Thailand. Abstract No. MoOrB1055. Retrieved January 14, 2005, from http://www.iasociety.org/ejias
  • 19
    • 0034128937 scopus 로고    scopus 로고
    • Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits
    • Flexner C. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits. Annual Review of Pharmacology and Toxicology 40 (2000) 649-674
    • (2000) Annual Review of Pharmacology and Toxicology , vol.40 , pp. 649-674
    • Flexner, C.1
  • 20
    • 12144286934 scopus 로고    scopus 로고
    • Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?
    • Fontas E., van Leth F., Sabin C.A., Friis-Moller N., Rickenbach M., d'Arminio Monforte A., et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?. Journal of Infectious Diseases 189 (2004) 1056-1074
    • (2004) Journal of Infectious Diseases , vol.189 , pp. 1056-1074
    • Fontas, E.1    van Leth, F.2    Sabin, C.A.3    Friis-Moller, N.4    Rickenbach, M.5    d'Arminio Monforte, A.6
  • 21
    • 0345064200 scopus 로고    scopus 로고
    • Combination antiretroviral therapy and the risk of myocardial infarction
    • Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
    • Friis-Moller N., Sabin C.A., Weber R., d'Arminio Monforte, A El-Sadr W.M., Reiss P., et al., Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine 349 (2003) 1993-2003
    • (2003) New England Journal of Medicine , vol.349 , pp. 1993-2003
    • Friis-Moller, N.1    Sabin, C.A.2    Weber, R.3    d'Arminio Monforte4    A El-Sadr, W.M.5    Reiss, P.6
  • 22
    • 2042469458 scopus 로고    scopus 로고
    • Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome
    • Gianotti N., Soria A., Galli L., Giudici B., Fusetti G., Lazzarin A., et al. Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome. AIDS 18 (2004) 821-823
    • (2004) AIDS , vol.18 , pp. 821-823
    • Gianotti, N.1    Soria, A.2    Galli, L.3    Giudici, B.4    Fusetti, G.5    Lazzarin, A.6
  • 23
  • 24
    • 33847323406 scopus 로고    scopus 로고
    • Harley W., DeJesus E., Pistole M., Sension M., Garrett L., Nettler S., et al. (2001, February). A 24-week randomized, controlled, open-label evaluation of adherence and convenience of continuing indinavir versus switching to ritonavir/indinavir 400 mg/400 mg BID (The NICE Study). Paper presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. Abstract No. 334.
  • 25
    • 20144365012 scopus 로고    scopus 로고
    • Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results
    • Kashuba A.D., Tierney C., Downey G.F., Acosta E.P., Vergis E.N., Klingman K., et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 19 (2005) 145-152
    • (2005) AIDS , vol.19 , pp. 145-152
    • Kashuba, A.D.1    Tierney, C.2    Downey, G.F.3    Acosta, E.P.4    Vergis, E.N.5    Klingman, K.6
  • 26
    • 33847305352 scopus 로고    scopus 로고
    • Katlama C., Arasteh K., Clotet B., Cooper D., Henry K., Lalezari J., et al. (2003, July). Enfuvirtide TORO studies: 48 week results confirm 24 week findings. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France. Abstract No. LB02.
  • 27
    • 33847315495 scopus 로고    scopus 로고
    • Katlama C., Berger D., Bellos N., Grinsztejn B., Haubrich R., Wilkin T., et al. (2005, February). Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA. Abstract No. 164LB.
  • 28
    • 0037648770 scopus 로고    scopus 로고
    • Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers
    • Kurowski M., Sternfeld T., Sawyer A., Hill A., and Mocklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Medicine 4 (2003) 94-100
    • (2003) HIV Medicine , vol.4 , pp. 94-100
    • Kurowski, M.1    Sternfeld, T.2    Sawyer, A.3    Hill, A.4    Mocklinghoff, C.5
  • 30
    • 33847299949 scopus 로고    scopus 로고
    • Lundgren J. D., Hill A., Fox Z., Clumeck N., Bruun J. N., Benetucci J., et al on behalf of the MaxCmin Trial Group. (2003, July). Hepatotoxicity of ritonavir-boosted indinavir (IDV/r 800/100 mg twice daily) and saquinavir (SAQ/r 1000/100 mg twice daily) in a phase IV, randomized, open-label, and multicentre trial in adult HIV-1 infection: the MaxCmin1 Trial. Paper presented at the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, France.
  • 31
    • 11144357725 scopus 로고    scopus 로고
    • Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir
    • Martinez E., Domingo P., Galindo M.J., Milinkovic A., Arroyo J.A., Baldori F., et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clinical Infectious Diseases 38 (2004) 1017-1023
    • (2004) Clinical Infectious Diseases , vol.38 , pp. 1017-1023
    • Martinez, E.1    Domingo, P.2    Galindo, M.J.3    Milinkovic, A.4    Arroyo, J.A.5    Baldori, F.6
  • 32
    • 1642403331 scopus 로고    scopus 로고
    • Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men
    • Clinical Epidemiology Group from the French Hospital Database (2003)
    • Mary-Krause M., Cotte L., Simon A., Partisani M., Costagliola D., and Clinical Epidemiology Group from the French Hospital Database (2003). Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17 (2003) 2479-2486
    • (2003) AIDS , vol.17 , pp. 2479-2486
    • Mary-Krause, M.1    Cotte, L.2    Simon, A.3    Partisani, M.4    Costagliola, D.5
  • 33
    • 33847253339 scopus 로고    scopus 로고
    • McCallister S., Kohlbrenner V., Villacian J., Mukwaya G., Neubacher D., Mayers D. (2004, December). 24-week combined analysis for the TPV RESIST studies of 1483 treatment-experienced patients given either tipranavir/ritonavir (TPV/r) or an optimized standard of care regimen using 1 of 4 RTV-boosted comparator PIs (CPI/r). Paper presented at the HIV DART 2004, Montego Bay, Jamaica. Abstract No. 060.
  • 34
    • 33847322938 scopus 로고    scopus 로고
    • Neubacher D., Markowitz M., Slater L., Curry R., Mayers D., McCallister S. (2003, October). Long-term 80-week follow-up of highly treatment-experienced (HTE) patients on tipranavir-based antiretroviral therapy (BI 1182.2). Paper presented at the 9th European AIDS Conference, Warsaw, Poland.
  • 37
    • 33847266189 scopus 로고    scopus 로고
    • Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. May 4, 2006. Retrieved June 13, 2006, from http://aidsinfo.nih.gov/guidelines
  • 38
    • 33644661382 scopus 로고    scopus 로고
    • Evaluation of coronary artery calcification by electron beam computed tomography (EBCT) in HIV-infected men receiving prolonged protease inhibitor (PI) therapy
    • Abstract No. 116
    • Parenti D.M., Klouj A., Rice M.M., Roberts A.D., Liappis A.P., Bisby N., et al. Evaluation of coronary artery calcification by electron beam computed tomography (EBCT) in HIV-infected men receiving prolonged protease inhibitor (PI) therapy. Antiviral Therapy 9 (2004) L65 Abstract No. 116
    • (2004) Antiviral Therapy , vol.9
    • Parenti, D.M.1    Klouj, A.2    Rice, M.M.3    Roberts, A.D.4    Liappis, A.P.5    Bisby, N.6
  • 39
    • 33847318612 scopus 로고    scopus 로고
    • Podzamczer D., Tressler R., Flexner C., Katlama C., Havlir D., Letendre S., et al. (2004, July). Higher doses of lopinavir/ritonavir (LPV/r) in highly treatment-experienced, HIV-infected patients: 48-week safety/efficacy evaluation. Poster presented at the 15th International AIDS Conference, Bangkok, Thailand. Poster TuPeB4555.
  • 41
    • 10244222704 scopus 로고    scopus 로고
    • Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir
    • Sulkowski M.S., Mehta S.H., Chaisson R.E., Thomas D.L., and Moore R.D. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 18 (2004) 2277-2284
    • (2004) AIDS , vol.18 , pp. 2277-2284
    • Sulkowski, M.S.1    Mehta, S.H.2    Chaisson, R.E.3    Thomas, D.L.4    Moore, R.D.5
  • 42
    • 17344370085 scopus 로고    scopus 로고
    • Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection
    • Visnegarwala F., Chen L., Raghavan S., and Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. Journal of Infection 50 (2005) 331-337
    • (2005) Journal of Infection , vol.50 , pp. 331-337
    • Visnegarwala, F.1    Chen, L.2    Raghavan, S.3    Tedaldi, E.4
  • 43
    • 0034493003 scopus 로고    scopus 로고
    • Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests
    • Vora S., Michon C., Junet C., Belavoine J.F., Renold-Moynier C., Yerly S., et al. Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests. AIDS 14 (2000) 2795-2797
    • (2000) AIDS , vol.14 , pp. 2795-2797
    • Vora, S.1    Michon, C.2    Junet, C.3    Belavoine, J.F.4    Renold-Moynier, C.5    Yerly, S.6
  • 44
    • 0032558803 scopus 로고    scopus 로고
    • Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
    • Walli R., Herfort O., Michl G.M., Demant T., Jager H., Dieterle C., et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. IDS 12 (1998) F167-F173
    • (1998) IDS , vol.12
    • Walli, R.1    Herfort, O.2    Michl, G.M.3    Demant, T.4    Jager, H.5    Dieterle, C.6
  • 45
    • 33847291722 scopus 로고    scopus 로고
    • Walmsley S., Benetucci J., Brutus A., Clumeck N., Dragsted U. B., Gazzard, B, et al. (2004, February). Lipid profiles of patients enrolled in the MaxCmin2 trial: A randomized, open-label, multicenter comparative trial evaluating the safety and efficacy of lopinavir/ritonavir (LPV/r; 400/100 MG bid) versus saquinavir/ritonavir (SAQ/r; 1000/100 MG bid). Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
  • 46
    • 33847277022 scopus 로고    scopus 로고
    • Weber R., Friis-Moller N., Sabin C., Reiss P., D'Arminio Monforte A., Dabis F., et al. (2005, February). HIV and non-HIV-related deaths and their relationship to immunodeficiency: The D:A:D Study. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
  • 47
    • 0141458274 scopus 로고    scopus 로고
    • Tipranavir: A protease inhibitor from a new class with distinct antiviral activity
    • Yeni P. Tipranavir: A protease inhibitor from a new class with distinct antiviral activity. Journal of Acquired Immune Deficiency Syndrome 34 Suppl. 1 (2003) S91-S94
    • (2003) Journal of Acquired Immune Deficiency Syndrome , vol.34 , Issue.SUPPL. 1
    • Yeni, P.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.